Brief: UroGen Pharma Reports Q4 Loss Per Share Of $1.27

UroGen Pharma

21/03/2022 12:47

March 21 (Reuters) - Urogen Pharma Ltd  UR8.F :
    * UROGEN PHARMA REPORTS FOURTH QUARTER AND FULL-YEAR 2021
FINANCIAL RESULTS AND RECENT CORPORATE DEVELOPMENTS
    * Q4 LOSS PER SHARE $1.27
    * NET PRODUCT REVENUE OF JELMYTO FOR Q4 2021 OF $16.2
MILLION
    * UROGEN PHARMA - AS OF DEC 31, 2021, CASH, EQUIVALENTS,
MARKETABLE SECURITIES TOTALED $89.8 MILLION, DOES NOT INCLUDE
FIRST TRANCHE OF TERM LOAN FACILITY
    * ANTICIPATES FULL YEAR 2022 NET PRODUCT REVENUES FROM
JELMYTO TO
BE IN RANGE OF $70 TO $80 MILLION
    * Q4 EARNINGS PER SHARE VIEW $-1.18, REVENUE VIEW $16.5
MILLION --
REFINITIV IBES DATA

Source text for Eikon:  ID:nBw2kXclZa 
Further company coverage:  UR8.F 

 ((Reuters.Briefs@thomsonreuters.com;))